FDA policy allowing compounding of unapproved peptides raises safety and development concerns

The Department of Health and Human Services recently approved the compounding of six peptide products that have not received FDA approval. This move expands the list of bulk substances that traditional pharmacies can prepare for patients.

Experts warn that offering experimental peptides without solid clinical data could expose patients to unknown risks. The lack of proven safety and efficacy makes the short‑term use of these compounds a potential hazard.

Beyond immediate safety concerns, the policy could undermine the incentives for pharmaceutical companies to invest in rigorous drug development. If patients can obtain untested peptides through compounding, the market for formally approved therapies may be weakened.

The FDA’s Pharmacy Compounding Advisory Committee had earlier recommended adding most of these peptides to the permissible list, signaling a shift toward broader access despite the unresolved evidence base.